Retrospective Study
Copyright ©The Author(s) 2021.
World J Clin Cases. Dec 6, 2021; 9(34): 10530-10539
Published online Dec 6, 2021. doi: 10.12998/wjcc.v9.i34.10530
Table 1 Demographic characteristics, n (%)
Parameters
Control group (n = 59)
Observation group (n = 59)
Sex
Male34 (57.63)32 (54.24)
Female25 (42.37)27 (45.76)
Age (yr)62.95 ± 9.0262.01 ± 9.75
Obstruction site
Low37 (62.71)31 (52.54)
High position22 (37.29)28 (47.46)
Disease type
Hilar cholangiocarcinoma33 (55.93)30 (50.08)
Middle-lower cholangiocarcinoma14 (23.73)15 (25.42)
Pancreatic Head Cancer4 (6.78)8 (13.56)
Ampullary carcinoma8 (13.56)6 (16.95)
Education
Junior high school and below8 (13.56)10 (16.95)
Technical secondary school and high school19 (32.30)17 (28.81)
College degree and above32 (54.24)32 (54.24)
Medical insurance
Medical insurance31 (52.54)27 (45.76)
Business insurance16 (27.12)17 (28.81)
Own expense12 (20.34)15 (25.42)
Table 2 Hospitalization after percutaneous transhepatic cholangiography drainage
Group
No. of days
Pipeline-related admissionsc
Control15.23 ± 3.028 (13.56)
Observation13.12 ± 2.15a1 (1.69)a
Table 3 Alkaline phosphatase, alanine aminotransferase, total bilirubin, and total bile acid before and after percutaneous transhepatic cholangiography drainage (mean ± SD)
Group
ALP (U/L)
ALT (U/L)
TBIL (μmol/L)
TBA (U/L)
Before
After
Before
After
Before
After
Before
After
Control 405.63 ± 53.69195.89 ± 23.16a121.36 ± 29.1249.23 ± 6.02a212.03 ± 41.26113.30 ± 24.03a115.23 ± 15.8628.23 ± 8.12a
Observation 412.05 ± 48.76184.25 ± 18.44a,c123.63 ± 25.7842.02 ± 5.69a,c204.96 ± 42.84104.89 ± 16.45a,c113.86 ± 19.1410.26 ± 2.47a,c
Table 4 White blood cell count and C-reactive protein before and after percutaneous transhepatic cholangiography drainage (mean ± SD)
Group
WBC (× 109/L)
CRP (mg/L)
Before
After
Before
After
Control 14.69 ± 2.158.45 ± 1.03a49.63 ± 5.2323.03 ± 4.11a
Observation14.71 ± 2.327.91 ± 0.89a,c50.01 ± 5.4117.56 ± 2.53a,c
Table 5 Percutaneous transhepatic cholangiography drainage prolapse, n (%)
Group
None
Partial
Complete
Escape rate
Control 48 (81.36)8 (13.56)3 (5.08)11 (18.64)
Observation57 (96.61)2 (3.39)0 (0.00)2 (3.39)a
Table 6 Complications after percutaneous transhepatic cholangiography drainage, n (%)
Group
Bleeding
Pancreatitis
Biliary tract
Blocked stent infection
Total
Control3 (5.08)1 (1.69)4 (6.78)2 (3.39)10 (16.95)
Observation1 (1.69)0 (0.00)2 (3.39)0 (0.00)3 (5.08)a
Table 7 Tube-related knowledge mastery scores before and after percutaneous transhepatic cholangiography drainage (mean ± SD)
Group
PTCD tube care
Complications
Drainage fluid
Wound care
Before
After
Before
After
Before
After
Before
After
Control5.15 ± 0.547.23 ± 0.46c4.85 ± 0.397.14 ± 0.55c5.03 ± 0.417.25 ± 0.45c5.63 ± 0.417.74 ± 0.46c
Observation5.06 ± 0.618.72 ± 0.51a,c4.82 ± 0.458.83 ± 0.57a,c5.10 ± 0.388.57 ± 0.43a,c5.58 ± 0.469.14 ± 0.41a,c
Table 8 Quality of life scores before and after percutaneous transhepatic cholangiography drainage (mean ± SD, min)
Parameter
Control group
Observation group
Before
After
Before
After
Fatigue78.23 ± 8.6932.63 ± 5.3677.96 ± 10.0323.05 ± 4.96
Pain66.23 ± 9.6535.26 ± 4.8565.96 ± 10.0219.36 ± 5.02
Nausea and vomiting68.77 ± 10.4530.36 ± 4.1269.02 ± 9.5218.26 ± 3.69
Itching65.32 ± 9.2122.05 ± 8.1464.53 ± 10.2314.26 ± 4.12
Emaciation62.55 ± 4.8541.05 ± 3.8662.85 ± 5.1732.63 ± 4.02
Fever58.69 ± 8.9627.41 ± 6.1159.04 ± 9.4122.03 ± 4.01